## F Susan Wong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3742399/publications.pdf

Version: 2024-02-01

57758 46799 8,543 149 44 89 citations h-index g-index papers 153 153 153 9834 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature, 2008, 455, 1109-1113.	27.8	1,745
2	Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nature Medicine, 1999, 5, 1026-1031.	30.7	420
3	Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. Journal of Clinical Investigation, $2007, 117, 3857-3867$ .	8.2	369
4	CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells Journal of Experimental Medicine, 1996, 183, 67-76.	8.5	321
5	The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. Journal of Autoimmunity, 2016, 66, 76-88.	6.5	227
6	Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clinical and Experimental Immunology, 2010, 163, 33-49.	2.6	213
7	The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity. Reviews in Endocrine and Metabolic Disorders, 2015, 16, 55-65.	5.7	207
8	Presentation of Antigen by Endothelial Cells and Chemoattraction Are Required for Homing of Insulin-specific CD8+ T Cells. Journal of Experimental Medicine, 2003, 197, 643-656.	8.5	196
9	Autoreactive CD8 T Cells in Organ-Specific Autoimmunity. Immunity, 2002, 17, 1-6.	14.3	178
10	Investigation of the Role of B-Cells in Type 1 Diabetes in the NOD Mouse. Diabetes, 2004, 53, 2581-2587.	0.6	176
11	Immunoglobulin synthesis and generalized autoimmunity in mice congenitally deficient in $\hat{l}\pm\hat{l}^2(+)$ T cells. Nature, 1994, 369, 654-658.	27.8	175
12	Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Science Translational Medicine, 2017, 9, .	12.4	151
13	Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clinical and Experimental Immunology, 2009, 155, 156-165.	2.6	143
14	Long term effect of gut microbiota transfer on diabetes development. Journal of Autoimmunity, 2014, 53, 85-94.	6.5	143
15	The gut microbiota and Type 1 Diabetes. Clinical Immunology, 2015, 159, 143-153.	3.2	142
16	Microbial antigen mimics activate diabetogenic CD8 T cells in NOD mice. Journal of Experimental Medicine, 2016, 213, 2129-2146.	8.5	131
17	The Effect of Innate Immunity on Autoimmune Diabetes and the Expression of Toll-Like Receptors on Pancreatic Islets. Journal of Immunology, 2004, 172, 3173-3180.	0.8	127
18	NLRP3 deficiency protects from type 1 diabetes through the regulation of chemotaxis into the pancreatic islets. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11318-11323.	7.1	109

#	Article	IF	Citations
19	IFN-Î <sup>3</sup> Affects Homing of Diabetogenic T Cells. Journal of Immunology, 2001, 167, 6637-6643.	0.8	94
20	Maternal Antibiotic Treatment Protects Offspring from Diabetes Development in Nonobese Diabetic Mice by Generation of Tolerogenic APCs. Journal of Immunology, 2015, 195, 4176-4184.	0.8	89
21	In Vivo Evidence for the Contribution of Human Histocompatibility Leukocyte Antigen (Hla)-Dq Molecules to the Development of Diabetes. Journal of Experimental Medicine, 2000, 191, 97-104.	8.5	88
22	TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 303, H732-H742.	3.2	80
23	The Role of Tollâ€Like Receptors 3 and 9 in the Development of Autoimmune Diabetes in NOD Mice. Annals of the New York Academy of Sciences, 2008, 1150, 146-148.	3.8	76
24	The Role of Lymphocyte Subsets in Accelerated Diabetes in Nonobese Diabetic–Rat Insulin Promoter–B7-1 (NOD-RIP-B7-1) Mice. Journal of Experimental Medicine, 1998, 187, 1985-1993.	8.5	73
25	Neonatal Tumor Necrosis Factor α Promotes Diabetes in Nonobese Diabetic Mice by Cd154-Independent Antigen Presentation to Cd8+ T Cells. Journal of Experimental Medicine, 2000, 191, 225-238.	8.5	71
26	Activation of Insulin-Reactive CD8 T-Cells for Development of Autoimmune Diabetes. Diabetes, 2009, 58, 1156-1164.	0.6	67
27	The Role of CD4 vs. CD8 T Cells in IDDM. Journal of Autoimmunity, 1999, 13, 290-295.	6.5	66
28	Therapeutic Targeting of Syk in Autoimmune Diabetes. Journal of Immunology, 2010, 185, 1532-1543.	0.8	64
29	Formulation of hydrophobic peptides for skin delivery via coated microneedles. Journal of Controlled Release, 2017, 265, 2-13.	9.9	63
30	Inhibition of Diabetes by an Insulin-Reactive CD4 T-Cell Clone in the Nonobese Diabetic Mouse. Diabetes, 1997, 46, 1124-1132.	0.6	62
31	The regulatory role of DR4 in a spontaneous diabetes DQ8 transgenic model. Journal of Clinical Investigation, 2001, 107, 871-880.	8.2	61
32	IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice. Clinical Immunology, 2011, 139, 336-349.	3.2	60
33	Immune and Pancreatic $\hat{l}^2$ Cell Interactions in Type 1 Diabetes. Trends in Endocrinology and Metabolism, 2016, 27, 856-867.	7.1	60
34	The role of the innate immune system in destruction of pancreatic beta cells in NOD mice and humans with type I diabetes. Journal of Autoimmunity, 2016, 71, 26-34.	6.5	60
35	Evaluation of different mucosal microbiota leads to gut microbiota-based prediction of type $1$ diabetes in NOD mice. Scientific Reports, $2018$ , $8$ , $15451$ .	3.3	59
36	Analysis of structure and function relationships of an autoantigenic peptide of insulin bound to H-2Kd that stimulates CD8 T cells in insulin-dependent diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 5551-5556.	7.1	58

#	Article	IF	Citations
37	TRIF deficiency protects non-obese diabetic mice from type 1 diabetes by modulating the gut microbiota and dendritic cells. Journal of Autoimmunity, 2018, 93, 57-65.	6.5	58
38	Different immunological responses to early-life antibiotic exposure affecting autoimmune diabetes development in NOD mice. Journal of Autoimmunity, 2016, 72, 47-56.	6.5	57
39	B-Cells Promote Intra-Islet CD8+ Cytotoxic T-Cell Survival to Enhance Type 1 Diabetes. Diabetes, 2008, 57, 909-917.	0.6	56
40	Dendritic cells license regulatory B cells to produce IL-10 and mediate suppression of antigen-specific CD8 T cells. Cellular and Molecular Immunology, 2020, 17, 843-855.	10.5	56
41	IFN- $\hat{I}^3$ and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia, 2010, 53, 1451-1460.	6.3	53
42	Gut microbial metabolites alter IgA immunity in type $1$ diabetes. JCI Insight, 2020, $5$ , .	5.0	53
43	Induction of insulitis by glutamic acid decarboxylase peptide-specific and HLA-DQ8-restricted CD4(+) T cells from human DQ transgenic mice Journal of Clinical Investigation, 1998, 102, 947-957.	8.2	52
44	Hydrodynamic gene delivery in human skin using a hollow microneedle device. Journal of Controlled Release, 2017, 265, 120-131.	9.9	50
45	Protection of Islet Grafts Through Transforming Growth Factor-β–Induced Tolerogenic Dendritic Cells. Diabetes, 2013, 62, 3132-3142.	0.6	48
46	Type 1 diabetes and gut microbiota: Friend or foe?. Pharmacological Research, 2015, 98, 9-15.	7.1	48
47	Tollâ€Like Receptors and Diabetes. Annals of the New York Academy of Sciences, 2008, 1150, 123-132.	3.8	45
48	Dietary short-chain fatty acids protect against type 1 diabetes. Nature Immunology, 2017, 18, 484-486.	14.5	45
49	Antibiotics, gut microbiota, environment in early life and type 1 diabetes. Pharmacological Research, 2017, 119, 219-226.	7.1	44
50	Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy. International Journal of Pharmaceutics, 2019, 562, 303-312.	5.2	44
51	Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes. Diabetes, 2013, 62, 2849-2858.	0.6	43
52	The role of CD4 and CD8 T cells in type I diabetes in the NOD mouse. Research in Immunology, 1997, 148, 327-332.	0.9	42
53	TLR9 Deficiency Promotes CD73 Expression in T Cells and Diabetes Protection in Nonobese Diabetic Mice. Journal of Immunology, 2013, 191, 2926-2937.	0.8	41
54	Transgenes and knockout mutations in animal models of type $1$ diabetes and multiple sclerosis. Immunological Reviews, 1999, 169, 93-106.	6.0	40

#	Article	IF	Citations
55	B Cells in Autoimmune Diabetes. Review of Diabetic Studies, 2005, 2, 121-121.	1.3	39
56	Beta cell function and ongoing autoimmunity in long-standing, childhood onset type 1 diabetes. Diabetologia, 2016, 59, 2722-2726.	6.3	37
57	Adoptive Transfer of mRNA-Transfected T Cells Redirected against Diabetogenic CD8ÂT Cells Can Prevent Diabetes. Molecular Therapy, 2017, 25, 456-464.	8.2	36
58	Nucleotide-binding oligomerization domain-containing protein 2 (Nod2) modulates T1DM susceptibility by gut microbiota. Journal of Autoimmunity, 2017, 82, 85-95.	6.5	36
59	Norovirus Changes Susceptibility to Type 1 Diabetes by Altering Intestinal Microbiota and Immune Cell Functions. Frontiers in Immunology, 2019, 10, 2654.	4.8	35
60	Inhibition of Membrane Type-1 Matrix Metalloproteinase by Cancer Drugs Interferes with the Homing of Diabetogenic T Cells into the Pancreas. Journal of Biological Chemistry, 2005, 280, 27755-27758.	3.4	33
61	Environmental Determinants of Type $1$ Diabetes: From Association to Proving Causality. Frontiers in Immunology, 2021, 12, 737964.	4.8	33
62	The Role of $Gr1+$ Cells after Anti-CD20 Treatment in Type 1 Diabetes in Nonobese Diabetic Mice. Journal of Immunology, 2012, 188, 294-301.	0.8	32
63	Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes. Journal of Controlled Release, 2016, 223, 178-187.	9.9	32
64	Characteristics of slow progression to diabetes in multiple islet autoantibody-positive individuals from five longitudinal cohorts: the SNAIL study. Diabetologia, 2018, 61, 1484-1490.	6.3	32
65	Antiâ€< scp>CD3 treatment upâ€regulates programmed cell death proteinâ€1 expression on activated effector T cells and severely impairs their inflammatory capacity. Immunology, 2017, 151, 248-260.	4.4	29
66	Distortion of the Major Histocompatibility Complex Class I Binding Groove to Accommodate an Insulin-derived 10-Mer Peptide. Journal of Biological Chemistry, 2015, 290, 18924-18933.	3.4	28
67	Altered Gut Microbiota Activate and Expand Insulin B15-23–Reactive CD8+ T Cells. Diabetes, 2019, 68, 1002-1013.	0.6	28
68	Targeted suppression of autoreactive CD8+ T-cell activation using blocking anti-CD8 antibodies. Scientific Reports, 2016, 6, 35332.	3.3	27
69	An increased frequency of NK cell receptor and HLA-C group 1 combinations in early-onset type 1 diabetes. Diabetologia, 2011, 54, 3062-3070.	6.3	26
70	Crosstalk between circadian rhythms and the microbiota. Immunology, 2020, 161, 278-290.	4.4	26
71	Immunology of Diabetes Society Tâ€Cell Workshop: HLA class I tetramerâ€directed epitope validation initiative Tâ€Cell Workshop Report—HLA Class I Tetramer Validation Initiative. Diabetes/Metabolism Research and Reviews, 2011, 27, 720-726.	4.0	25
72	The Dual Effects of B Cell Depletion on Antigen-Specific T Cells in BDC2.5NOD Mice. Journal of Immunology, 2012, 188, 4747-4758.	0.8	24

#	Article	IF	Citations
73	Materno-Fetal Transfer of Preproinsulin Through the Neonatal Fc Receptor Prevents Autoimmune Diabetes. Diabetes, 2015, 64, 3532-3542.	0.6	24
74	Toll-like receptor 9 negatively regulates pancreatic islet beta cell growth and function in a mouse model of type 1 diabetes. Diabetologia, 2018, 61, 2333-2343.	6.3	24
75	The Study of HLA Class II and Autoimmune Diabetes. Current Molecular Medicine, 2003, 3, 1-15.	1.3	22
76	IRAK-M Deficiency Promotes the Development of Type 1 Diabetes in NOD Mice. Diabetes, 2014, 63, 2761-2775.	0.6	22
77	Hepatitis mouse models: from acuteâ€toâ€chronic autoimmune hepatitis. International Journal of Experimental Pathology, 2014, 95, 309-320.	1.3	22
78	A reproducible method for the expansion of mouse CD8 + T lymphocytes. Journal of Immunological Methods, 2015, 417, 134-138.	1.4	22
79	Combinatorial detection of autoreactive CD8+ T cells with HLA-A2 multimers: a multi-centre study by the Immunology of Diabetes Society T Cell Workshop. Diabetologia, 2018, 61, 658-670.	6.3	22
80	Targeting proinsulin to local immune cells using an intradermal microneedle delivery system; a potential antigen-specific immunotherapy for type $1$ diabetes. Journal of Controlled Release, 2020, 322, 593-601.	9.9	21
81	Immunotargeting of insulin reactive CD8 T cells to prevent Diabetes. Journal of Autoimmunity, 2010, 35, 390-397.	6.5	20
82	Mouse Models of Autoimmune Diabetes: The Nonobese Diabetic (NOD) Mouse. Methods in Molecular Biology, 2020, 2128, 87-92.	0.9	20
83	Peripheral Proinsulin Expression Controls Low-Avidity Proinsulin-Reactive CD8 T Cells in Type 1 Diabetes. Diabetes, 2016, 65, 3429-3439.	0.6	19
84	Topical steroid therapy induces proâ€tolerogenic changes in Langerhans cells in human skin. Immunology, 2015, 146, 411-422.	4.4	18
85	Fine-Needle Aspiration Biopsy of the Lymph Node: A Novel Tool for the Monitoring of Immune Responses after Skin Antigen Delivery. Journal of Immunology, 2015, 195, 386-392.	0.8	18
86	B cell depletion reduces T cell activation in pancreatic islets in a murine autoimmune diabetes model. Diabetologia, 2018, 61, 1397-1410.	6.3	18
87	Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8+ T cells and exhibit a distinct CD95hi B cell phenotype. Diabetologia, 2020, 63, 1174-1185.	6.3	18
88	IFNâ€Î± Can Both Protect against and Promote the Development of Type 1 Diabetes. Annals of the New York Academy of Sciences, 2008, 1150, 187-189.	3.8	16
89	Phenotypically distinct anti-insulin B cells repopulate pancreatic islets after anti-CD20 treatment in NOD mice. Diabetologia, 2019, 62, 2052-2065.	6.3	14
90	Using gold nanoparticles for enhanced intradermal delivery of poorly soluble auto-antigenic peptides. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 32, 102321.	3.3	14

#	Article	IF	CITATIONS
91	Toll-like receptor 7 deficiency suppresses type 1 diabetes development by modulating B-cell differentiation and function. Cellular and Molecular Immunology, 2021, 18, 328-338.	10.5	13
92	IL-10 Deficiency Accelerates Type 1 Diabetes Development via Modulation of Innate and Adaptive Immune Cells and Gut Microbiota in BDC2.5 NOD Mice. Frontiers in Immunology, 2021, 12, 702955.	4.8	13
93	Loss of CXCR3 expression on memory B cells in individuals with long-standing type 1 diabetes. Diabetologia, 2018, 61, 1794-1803.	6.3	12
94	Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type $1$ diabetes. Immunotherapy Advances, 2022, 2, .	3.0	12
95	Insulin – a primary autoantigen in type 1 diabetes?. Trends in Molecular Medicine, 2005, 11, 445-448.	6.7	11
96	Targeted expression of the anti-apoptotic gene CrmA to NOD pancreatic islets protects from autoimmune diabetes. Journal of Autoimmunity, 2006, 26, 7-15.	6.5	11
97	To B or not to Bâ€"pathogenic and regulatory B cells in autoimmune diabetes. Current Opinion in Immunology, 2010, 22, 723-731.	5.5	11
98	Hyperglycaemia does not affect antigen-specific activation and cytolytic killing by CD8+ T cells $\langle i \rangle$ in $vivo\langle i \rangle$ . Bioscience Reports, 2017, 37, .	2.4	11
99	Modulation of the immune system by the gut microbiota in the development of type 1 diabetes. Human Vaccines and Immunotherapeutics, 2018, 14, 1-17.	3.3	11
100	Regulatory B Cells: Role in Type 1 Diabetes. Frontiers in Immunology, 2021, 12, 746187.	4.8	11
101	What can the HLA transgenic mouse tell us about autoimmune diabetes?. Diabetologia, 2004, 47, 1476-1487.	6.3	10
102	Circadian Rhythm Modulation of Microbes During Health and Infection. Frontiers in Microbiology, 2021, 12, 721004.	3.5	10
103	Endoplasmic Reticulum Targeting Alters Regulation of Expression and Antigen Presentation of Proinsulin. Journal of Immunology, 2014, 192, 4957-4966.	0.8	9
104	Proinsulin Expression Shapes the TCR Repertoire but Fails to Control the Development of Low-Avidity Insulin-Reactive CD8+T Cells. Diabetes, 2016, 65, 1679-1689.	0.6	9
105	Activation-induced cytidine deaminase deficiency accelerates autoimmune diabetes in NOD mice. JCI Insight, 2018, 3, .	5.0	9
106	Activated but functionally impaired memory Tregs are expanded in slow progressors to type $1$ diabetes. Diabetologia, 2022, 65, 343-355.	6.3	9
107	The Influence of the Major Histocompatibility Complex on Development of Autoimmune Diabetes in RIP-B7.1 Mice. Diabetes, 2005, 54, 2032-2040.	0.6	8
108	Antiâ€CD20 Treatment Prolongs Syngeneic Islet Graft Survival and Delays the Onset of Recurrent Autoimmune Diabetes. Annals of the New York Academy of Sciences, 2008, 1150, 217-219.	3.8	8

#	Article	IF	Citations
109	Regulatory T cells in autoimmune endocrine diseases. Trends in Endocrinology and Metabolism, 2008, 19, 292-299.	7.1	8
110	CD8+ T-cells and their interaction with other cells in damage to islet $\hat{l}^2$ -cells. Biochemical Society Transactions, 2008, 36, 316-320.	3.4	8
111	TLR9 Deficiency in B Cells Promotes Immune Tolerance via Interleukin-10 in a Type 1 Diabetes Mouse Model. Diabetes, 2021, 70, 504-515.	0.6	8
112	Functional inhibition related to structure of a highly potent insulinâ€specific CD8 T cell clone using altered peptide ligands. European Journal of Immunology, 2008, 38, 240-249.	2.9	7
113	Immunotherapy for T1DMâ€"targeting innate immunity. Nature Reviews Endocrinology, 2013, 9, 384-385.	9.6	7
114	A predictive CD8+ T cell phenotype for T1DM progression. Nature Reviews Endocrinology, 2020, 16, 198-199.	9.6	7
115	Innate immunity in latent autoimmune diabetes in adults. Diabetes/Metabolism Research and Reviews, 2022, 38, e3480.	4.0	7
116	Inflammasomes and Type 1 Diabetes. Frontiers in Immunology, 2021, 12, 686956.	4.8	7
117	Artemether and aspterric acid induce pancreatic alpha cells to transdifferentiate into beta cells in zebrafish. British Journal of Pharmacology, $2021$ , , .	5.4	7
118	Detecting autoreactive B cells in the peripheral blood of people with type 1 diabetes using ELISpot. Journal of Immunological Methods, 2019, 471, 61-65.	1.4	6
119	Developing a Novel Model System to Target Insulinâ€Reactive CD8 T Cells. Annals of the New York Academy of Sciences, 2008, 1150, 54-58.	3.8	5
120	T Cells Recognizing a Peptide Contaminant Undetectable by Mass Spectrometry. PLoS ONE, 2011, 6, e28866.	2.5	5
121	Selective immunotargeting of diabetogenic <scp>CD</scp> 4 T cells by genetically redirected T cells. Immunology, 2014, 143, 609-617.	4.4	5
122	Altered Systemic and Intestinal IgA Immune Responses in Individuals With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4616-e4625.	3.6	5
123	Antigen presenting cellâ€targeted proinsulin expression converts insulinâ€specific CD8 + Tâ€cell priming to tolerance in autoimmuneâ€prone NOD mice. European Journal of Immunology, 2017, 47, 1550-1561.	2.9	4
124	Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production. PLoS ONE, 2016, 11, e0146516.	2.5	4
125	IgM-associated gut bacteria in obesity and type 2 diabetes in C57BL/6 mice and humans. Diabetologia, 2022, 65, 1398-1411.	6.3	4
126	Stimulating IL-13 Receptors on T cells: A New Pathway for Tolerance Induction in Diabetes?Â. Diabetes, 2011, 60, 1657-1659.	0.6	3

#	Article	IF	CITATIONS
127	Identification of Islet Antigen-Specific CD8 T Cells Using MHCI-Peptide Tetramer Reagents in the Non Obese Diabetic (NOD) Mouse Model of Type 1 Diabetes. Methods in Molecular Biology, 2015, 1433, 119-125.	0.9	3
128	The Gut Microbiome in the NOD Mouse. Methods in Molecular Biology, 2016, 1433, 169-177.	0.9	3
129	ldentifying the â€ʿAchilles heel' of type 1 diabetes. Clinical and Experimental Immunology, 2021, 204, 167-178.	2.6	3
130	Natural Protection From Type 1 Diabetes in NOD Mice Is Characterized by a Unique Pancreatic Islet Phenotype. Diabetes, 2021, 70, 955-965.	0.6	3
131	Incidence of diabetic retinopathy in newly diagnosed subjects with type 2 diabetes mellitus over 5Âyears: Contribution of Î'-cell function. Journal of Diabetes and Its Complications, 2022, 36, 108028.	2.3	3
132	Type 1 Diabetes Therapy Beyond T Cell Targeting: Monocytes, B Cells, and Innate Lymphocytes. Review of Diabetic Studies, 2012, 9, 289-304.	1.3	3
133	Obesity aggravates contact hypersensitivity reaction in mice. Contact Dermatitis, 2022, 87, 28-39.	1.4	3
134	Tracking Immunological Responses of Islet Antigen-Specific T Cells in the Nonobese Diabetic (NOD) Mouse Model of Type 1 Diabetes. Methods in Molecular Biology, 2015, 1433, 127-134.	0.9	2
135	Adoptive Transfer of Autoimmune Diabetes Using Immunodeficient Nonobese Diabetic (NOD) Mice. Methods in Molecular Biology, 2015, 1433, 135-140.	0.9	2
136	APCâ€ŧargeted proinsulin expression inactivates insulinâ€specific memory CD8 + T cells in NOD mice. Immunology and Cell Biology, 2017, 95, 765-774.	2.3	2
137	Regulation of contact sensitivity in nonâ€obese diabetic (NOD) mice by innate immunity. Contact Dermatitis, 2018, 79, 197-207.	1.4	2
138	Historical and new insights into pathogenesis of type 1 diabetes. Clinical and Experimental Immunology, 2019, 198, 292-293.	2.6	2
139	A Novel Method for Concurrent Visualization of Immunostain Under Light and Electron Microscopy in Pancreatic Islets. Journal of Histochemistry and Cytochemistry, 1998, 46, 1341-1345.	2.5	1
140	How Does B-Cell Tolerance Contribute to the Protective Effects of Diabetes Following Induced Mixed Chimerism in Autoimmune Diabetes?. Diabetes, 2014, 63, 1855-1857.	0.6	1
141	Insulin-Reactive T Cells Convert Diabetogenic Insulin-Reactive VH125 B Cells Into Tolerogenic Cells by Reducing Germinal Center T:B Cell Interactions in NOD Mice. Frontiers in Immunology, 2020, 11, 585886.	4.8	1
142	Regulatory B Cells in Type 1 Diabetes. Methods in Molecular Biology, 2021, 2270, 419-435.	0.9	1
143	Historical and new insights into pathogenesis of type 1 diabetes (2). Clinical and Experimental Immunology, 2021, 204, 165-166.	2.6	1
144	Assessing Immune Responses in the Nonobese Diabetic Mouse Model of Type 1 Diabetes. Methods in Molecular Biology, 2020, 2128, 269-289.	0.9	1

#	Article	IF	CITATIONS
145	Correction: The Role of Gr1+ Cells after Anti-CD20 Treatment in Type 1 Diabetes in Nonobese Diabetic Mice. Journal of Immunology, 2012, 188, 3552-3552.	0.8	O
146	Differentiating MHC-Dependent and -Independent Mechanisms of Lymph Node Stromal Cell Regulation of Proinsulin-Specific CD8+ T Cells in Type 1 Diabetes. Diabetes, 2021, 70, 529-537.	0.6	0
147	Referral rates of patients with diabetes to secondary care are inversely related to the prevalence of diabetes in each primary care practice and confidence in treatment, not to HbA1c level. Primary Care Diabetes, 2021, 15, 513-517.	1.8	O
148	Role of the enviroment in the pathogenesis of type $1$ diabetes. Endocrine Abstracts, $0$ , , .	0.0	0
149	Editorial: Immunopathology of Type 1 Diabetes. Frontiers in Immunology, 2022, 13, 852963.	4.8	0